Skip to main content
Premium Trial:

Request an Annual Quote

Cell Signaling Technology Renews Research Pact with Ortho Biotech

NEW YORK (GenomeWeb News) – Cell Signaling Technology has renewed a biomarker research agreement with Ortho Biotech Oncology Research & Development, a unit of Johnson & Johnson Pharmaceutical Research & Development.
 
Danvers, Mass.-based CST said that it would use its PhosphoScan and PTMScan technologies in research aimed at discovering and validating biomarkers for multiple enzyme target classes and lead small-molecule inhibitors for cancer treatment. The technologies are used for profiling and discovery of phosphorylation and other post-translational modifications in cells and tissues.
 
Financial terms and other details of the collaboration were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.